{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:05:00Z","timestamp":1789387500286,"version":"build-2803163510"},"reference-count":98,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["21-75-30015"],"award-info":[{"award-number":["21-75-30015"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["21-75-30015"],"award-info":[{"award-number":["21-75-30015"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Although BRCA1 and BRCA2 remain the backbone for germline DNA testing of patients with breast cancer (BC) or ovarian cancer (OC), there are a number of other genes with proven or potential clinical significance. PALB2 is associated with an elevated risk of BC, whereas pathogenic variants (PVs) in RAD51C, RAD51D, and BRIP1 are mainly relevant to OC development. Some germline findings are helpful in guiding therapeutic decisions: for example, PALB2, RAD51C, and RAD51D germline PVs render tumors sensitive to PARP inhibitors (PARPi), whereas cancers arising in PTEN heterozygotes are likely to be responsive to AKT down-regulators. CHEK2, ATM, BLM, and NBN PVs result in only a two-fold or even lower excess of cancer risk. However, the incorporation of these genes in DNA testing panels may occasionally lead to the identification of individuals with biallelic germline inactivation; these patients have a severe disease phenotype and thus require intensive medical intervention. The accumulation of data on \u201cnon-BRCA\u201d BC- and OC-predisposing genes is complicated due to the rarity of their alterations, significant interethnic variations in population frequency of relevant PVs, heterogeneity of disease subtypes, etc. The use of extended gene panels, which pool together both clinically validated cancer-associated genes and \u201ccandidate\u201d genes with potential but unproven significance, is likely to be a prevailing diagnostic approach in the next few years; therefore, proper attitudes towards accumulation and interpretation of genetic data are important.<\/jats:p>","DOI":"10.3390\/curroncol33090556","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:19:41Z","timestamp":1789381181000},"page":"556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breast\u2013Ovarian Hereditary Cancer Syndrome: Beyond BRCA1 and BRCA2"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-7891","authenticated-orcid":false,"given":"Evgeny","family":"Imyanitov","sequence":"first","affiliation":[{"name":"Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint-Petersburg, Russia"},{"name":"Department of Medical Genetics, St.-Petersburg State Pediatric Medical University, 194100 Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-1609","authenticated-orcid":false,"given":"Anna","family":"Sokolenko","sequence":"additional","affiliation":[{"name":"Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint-Petersburg, Russia"},{"name":"Department of Medical Genetics, St.-Petersburg State Pediatric Medical University, 194100 Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2026.0007","article-title":"NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026","volume":"24","author":"Cheng","year":"2026","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.annonc.2025.04.012","article-title":"Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations","volume":"36","author":"Turnbull","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2023.07.017","article-title":"Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis","volume":"177","author":"Narayan","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ijc.33317","article-title":"Frequency and molecular characteristics of PALB2-associated cancers in Russian patients","volume":"148","author":"Preobrazhenskaya","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","article-title":"Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival","volume":"180","author":"Kahn","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.31557\/APJCP.2026.27.2.651","article-title":"Whole Exome Sequencing Revealed Rare Variants in BRCA2, RAD51D, FANGC, CYP24A1 Genes in Breast\/Ovarian Cancer Patients from a Small Buryat Ethnic Group","volume":"27","author":"Gervas","year":"2026","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2300454","DOI":"10.1200\/GO.23.00454","article-title":"Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer","volume":"10","author":"Feng","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kwong, A., Ho, C.Y.S., Au, C.H., Tey, S.K., and Ma, E.S.K. (2024). Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and\/or Ovarian Cancer Patients and Families. J. Pers. Med., 14.","DOI":"10.3390\/jpm14080866"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Hauke","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101230","DOI":"10.1016\/j.gim.2024.101230","article-title":"Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene","volume":"26","author":"Morgan","year":"2024","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13048-021-00809-w","article-title":"Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing","volume":"14","author":"Cummings","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.35475","article-title":"Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories","volume":"157","author":"Kasper","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a026187","DOI":"10.1101\/cshperspect.a026187","article-title":"Inherited TP53 Mutations and the Li-Fraumeni Syndrome","volume":"7","author":"Guha","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., Gonz\u00e1lez-Neira, A., Luccarini, C., Wahlstr\u00f6m, C., Pooley, K.A., Parsons, M.T., and Fortuno, C. (2021). Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women. N. Engl. J. Med., 384, 428\u2013439.","DOI":"10.1056\/NEJMoa1913948"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ajhg.2022.07.005","article-title":"Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants","volume":"109","author":"Brewer","year":"2022","journal-title":"Am. J. Hum. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/cge.13875","article-title":"A review on age-related cancer risks in PTEN hamartoma tumor syndrome","volume":"99","author":"Hendricks","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-022-06517-3","article-title":"Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability","volume":"192","author":"Iyevleva","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-023-07176-8","article-title":"Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants","volume":"204","author":"Schwartz","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/ijc.26342","article-title":"High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia","volume":"130","author":"Sokolenko","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41523-020-0163-1","article-title":"Prevalence of disease-causing genes in Japanese patients with BRCA1\/2-wildtype hereditary breast and ovarian cancer syndrome","volume":"6","author":"Kaneyasu","year":"2020","journal-title":"npj Breast Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12032-013-0828-9","article-title":"Development of breast tumors in CHEK2, NBN\/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele","volume":"31","author":"Suspitsin","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajog.2026.02.020","article-title":"Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: A systematic review and meta-analysis","volume":"235","author":"Ganesan","year":"2026","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Sampson","year":"2020","journal-title":"Genet. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/345075","article-title":"The founder mutation MSH21906G\u2192C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population","volume":"71","author":"Foulkes","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gcc.22759","article-title":"The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families","volume":"58","author":"Pinheiro","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ceglie, G., Del Baldo, G., Agolini, E., Rinelli, M., Cacchione, A., Del Bufalo, F., Vinci, M., Carta, R., Boccuto, L., and Miele, E. (2020). Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.561487"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1195-1203","article-title":"Founding mutations and Alu-mediated recombination in hereditary colon cancer","volume":"1","author":"Kristo","year":"1995","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10689-017-0067-x","article-title":"Haplotype analysis suggest that the MLH1 c.2059C>T mutation is a Swedish founder mutation","volume":"17","author":"Liu","year":"2018","journal-title":"Fam. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14755","DOI":"10.1038\/ncomms14755","article-title":"Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2","volume":"8","author":"Haraldsdottir","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1399-0004.2005.00537.x","article-title":"Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome","volume":"68","author":"Cederquist","year":"2005","journal-title":"Clin. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1399-0004.2010.01594.x","article-title":"Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome","volume":"79","author":"Raskin","year":"2011","journal-title":"Clin. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/cge.14784","article-title":"PMS2 c.2117del (p.Lys706Serfs19) is the Most Frequent Cancer-Associated Founder Pathogenic Variant in the French-Canadian Population of Quebec, Canada","volume":"108","author":"Chong","year":"2025","journal-title":"Clin. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-019-0115-9","article-title":"Homologous recombination DNA repair defects in PALB2-associated breast cancers","volume":"5","author":"Li","year":"2019","journal-title":"npj Breast Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/JCO-25-02075","article-title":"TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients with Metastatic Breast Cancer with Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2","volume":"44","author":"Tung","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2300091","DOI":"10.1200\/PO.23.00091","article-title":"Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients with Somatic BRCA1\/2, Germline PALB2, or Homologous Recombination Deficiency Signature","volume":"7","author":"Batalini","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e247811","DOI":"10.1001\/jamanetworkopen.2024.7811","article-title":"Prevalence of Homologous Recombination Deficiency Among Patients with Germline RAD51C\/D Breast or Ovarian Cancer","volume":"7","author":"Romey","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium, Mavaddat, N., Dorling, L., Carvalho, S., Allen, J., Gonz\u00e1lez-Neira, A., Keeman, R., Bolla, M.K., Dennis, J., and Wang, Q. (2022). Pathology of Tumors Associated with Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol., 8, e216744.","DOI":"10.1001\/jamaoncol.2021.6744"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yao, H., Li, N., and Yuan, H. (2022). Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10456-z"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ygyno.2020.09.040","article-title":"Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells","volume":"159","author":"Ciccone","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"114307","DOI":"10.1016\/j.ejca.2024.114307","article-title":"HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome","volume":"211","author":"Bottosso","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PAS.0000000000002338","article-title":"Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome","volume":"49","author":"Narasimhamurthy","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_49","first-page":"PO.19.00130","article-title":"Exceptional Response to AKT Inhibition in Patients with Breast Cancer and Germline PTEN Mutations","volume":"3","author":"Kingston","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-018-0951-9","article-title":"Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers","volume":"20","author":"Renault","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djy028","article-title":"The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers","volume":"110","author":"Weigelt","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-013-2692-x","article-title":"Clinical characteristics of breast cancer in patients with an NBS1 mutation","volume":"141","author":"Huzarski","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.12.005","article-title":"Ovarian cancer in Lynch syndrome; a systematic review","volume":"55","author":"Blok","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Capasso, I., Santoro, A., Lucci Cordisco, E., Perrone, E., Tronconi, F., Catena, U., Zannoni, G.F., Scambia, G., Fanfani, F., and Lorusso, D. (2023). Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051400"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"105758","DOI":"10.1016\/j.ebiom.2025.105758","article-title":"Impact of germline variants on breast and ovarian cancer risk in Japanese women: An original cohort study and meta-analysis","volume":"116","author":"Yazaki","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6601291","DOI":"10.1155\/humu\/6601291","article-title":"Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield","volume":"2026","author":"Bonamici","year":"2026","journal-title":"Hum. Mutat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Iyevleva, A.G., Aleksakhina, S.N., Sokolenko, A.P., Otradnova, E.A., Nikitina, A.S., Kashko, K.A., Syomina, M.V., Shestakova, A.D., Kuligina, E.S., and Morozova, N.S. (2025). Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas. Int. J. Mol. Sci., 26.","DOI":"10.21294\/1814-4861-2025-24-1-59-69"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kratz, C.P., Frone, M.N., Khincha, P.P., Hatton, J.N., Penkert, J., James, P.A., Spurdle, A.B., and Fortuno, C. (2026). Urgent need to recognize that Disease-Causing TP53 variants with atypical penetrance require distinct clinical recommendations. J. Natl. Cancer Inst., djag015.","DOI":"10.1093\/jnci\/djag015"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/521051","article-title":"Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation","volume":"81","author":"Teresi","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","article-title":"High risk of breast cancer in women with biallelic pathogenic variants in CHEK2","volume":"180","author":"Rainville","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101101","DOI":"10.1016\/j.gim.2024.101101","article-title":"The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2","volume":"26","author":"Cybulski","year":"2024","journal-title":"Genet. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41431-022-01270-z","article-title":"Two unrelated cases with biallelic CHEK2 variants: A novel condition with constitutional chromosomal instability?","volume":"31","author":"Bottillo","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10689-024-00420-0","article-title":"Asymptomatic Bloom syndrome diagnosed by chance in a patient with breast cancer","volume":"23","author":"Suspitsin","year":"2024","journal-title":"Fam. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e64170","DOI":"10.1002\/ajmg.a.64170","article-title":"Attenuated Form of Nijmegen Breakage Syndrome: Case Report of the Oldest Patient","volume":"197","author":"Gangal","year":"2025","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.spen.2024.101169","article-title":"Ataxia telangiectasia","volume":"52","author":"Collyer","year":"2024","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000452082","article-title":"Bloom\u2019s Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition","volume":"8","author":"Cunniff","year":"2017","journal-title":"Mol. Syndromol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Yanus, G.A., Suspitsin, E.N., and Imyanitov, E.N. (2024). The Spectrum of Disease-Associated Alleles in Countries with a Predominantly Slavic Population. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179335"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/s41588-024-01966-6","article-title":"Gene-based burden tests of rare germline variants identify six cancer susceptibility genes","volume":"56","author":"Ivarsdottir","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_71","unstructured":"National Center for Biotechnology Information (US) (2026, September 06). Lynch Syndrome, GeneReviews\u00ae, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1211\/."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2025.05.003","article-title":"Assessing preventive gynecologic decisions in individuals with Lynch syndrome","volume":"197","author":"Waggoner","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: Utility of a histology-based referral strategy","volume":"120","author":"Schrader","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1399-0004.2008.01111.x","article-title":"Estrogen receptor status in CHEK2-positive breast cancers: Implications for chemoprevention","volume":"75","author":"Cybulski","year":"2009","journal-title":"Clin. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-017-4388-0","article-title":"FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population","volume":"166","author":"Kiiski","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41523-021-00338-1","article-title":"Protein truncating variants in FANCM and risk for ER-negative\/triple negative breast cancer","volume":"7","author":"Peterlongo","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2024.10852","article-title":"Germline CDH1 Variants and Lifetime Cancer Risk","volume":"332","author":"Ryan","year":"2024","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/1055-9965.EPI-18-1102","article-title":"Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer","volume":"28","author":"Petridis","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/PGP.0000000000000369","article-title":"Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium","volume":"36","author":"Leo","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2017.01.005","article-title":"Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer","volume":"144","author":"Ryan","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41431-025-01786-0","article-title":"Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer","volume":"33","author":"Dicks","year":"2025","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-022-06782-2","article-title":"A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia","volume":"197","author":"Kechin","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/92.18.1529","article-title":"Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients","volume":"92","author":"Vahteristo","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.ejca.2004.09.008","article-title":"BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: A population-based study","volume":"40","author":"Rafnar","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1007\/s11033-019-04928-y","article-title":"New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients","volume":"46","author":"Gervas","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-023-07135-3","article-title":"Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus","volume":"203","author":"Sokolenko","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Grindedal, E.M., Heramb, C., Karsrud, I., Ariansen, S.L., M\u00e6hle, L., Undlien, D.E., Norum, J., and Schlichting, E. (2017). Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3422-2"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.27556","article-title":"Clinical significance of large rearrangements in BRCA1 and BRCA2","volume":"118","author":"Judkins","year":"2012","journal-title":"Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2006.044974","article-title":"A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer","volume":"43","author":"Cybulski","year":"2006","journal-title":"J. Med. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41431-020-0675-z","article-title":"Evaluation of CNV detection tools for NGS panel data in genetic diagnostics","volume":"28","author":"Castellanos","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/ng828","article-title":"Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors","volume":"30","author":"Chmiel","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/cup.13979","article-title":"Skin tumors in xeroderma pigmentosum: Evaluation of a large series and a literature review","volume":"48","author":"Baykal","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10689-012-9575-x","article-title":"Value of bilateral breast cancer for identification of rare recessive at-risk alleles: Evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation","volume":"12","author":"Kuligina","year":"2013","journal-title":"Fam. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.2217\/fon-2022-0358","article-title":"ROSALINE: A phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast","volume":"18","author":"Agostinetto","year":"2022","journal-title":"Future Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:13:10Z","timestamp":1789384390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":98,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090556"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090556","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}